Market access across Europe is becoming more challenging. Pricing pressure is increasing, health technology assessment processes are more rigorous, and healthcare systems are under growing financial strain. As a result, commercial conversations are shifting. Success is no longer driven by product differentiation alone, but by the ability to demonstrate clear system value. However, many organisations still treat value communication as a messaging exercise rather than a fully embedded operating model.

The Growing Complexity of Access in Europe

Access decisions are no longer made by a single stakeholder group.

They involve a complex network that includes prescribers, payers, hospital committees, regional decision-makers, and advocacy groups. Each stakeholder has different priorities, evidence requirements, and definitions of value.

A single, static narrative is no longer sufficient. Organisations must deliver tailored, evidence-based value propositions that resonate across multiple audiences.

Where Pharma Organisations Struggle

Despite strong clinical and economic data, execution often falls short.

Common challenges include:

• Messaging that is fragmented across medical, commercial, and access teams
• Overly cautious communication that limits impact and differentiation
• Ongoing tension between global consistency and local market needs

In many cases, value clearly exists but is not consistently or effectively communicated across stakeholders.

How Leading Organisations Are Operationalising Value

Companies that succeed in European market access take a more structured and cross-functional approach.

They align real world evidence generation directly to payer expectations and HTA requirements, ensuring relevance from the outset.

They build integrated teams across medical, commercial, and market access functions, creating a single, coherent value narrative that is consistently applied.

They also invest in capability building within the field. Sales teams are equipped to have economic and system-level conversations, not just clinical discussions.

Finally, they structure evidence in a modular way, allowing clinical outcomes, quality of life data, and economic impact to be tailored for different stakeholders and markets.

The Next Competitive Advantage in European Pharma

Value communication is becoming a defining factor in commercial performance.

Organisations that treat value as an operational capability, rather than a messaging exercise, will be better positioned to secure access across Europe.

This requires alignment across functions, clarity in evidence, and the ability to adapt to local market dynamics.

In Europe, value wins access. But only when it is operationalised across the organisation and delivered with consistency, credibility, and precision.